Medical/Pharmaceuticals Global News & Press Release Distribution

Medical/Pharmaceuticals

All
APAC

Appealing Data of CARsgen Therapeutics' CAR-T (CT041) in Advanced Gastric Cancer Presented at ESMO

SHANGHAI, Sept. 19, 2021 /PRNewswire/ -- On September 19, 2021, CARsgen Therapeutics (stock code: 2171.HK) disclosed the latest progress of the investigator-initiated trial (IIT) of Claudin18.2 (CLDN18.2) CAR-T (CT041) for the treatment of digestive system tumors. Results of this trial have been ...

2021-09-20 08:24 10721

Appealing Data of CARsgen Therapeutics' CAR-T (CT041) in Advanced Gastric Cancer Presented at ESMO

2021 CSCO | Henlius will Release Four Oral Presentations of Two Upcoming Commercial Products: Novel anti-PD-1 mAb Serplulimab and Bevacizumab Biosimilar

SHANGHAI, Sept. 18, 2021 /PRNewswire/ -- The 24th Annual Meeting of Chinese Society of Clinical Oncology (CSCO) will be held online and in-person from 25th to 29th September 2021. In this meeting, Henlius will release 4 study results of 2 products to be commercialized, the novel anti-PD-1 mAb ser...

2021-09-18 20:00 12628

Lunit AI Applied to Clinical Trial for Drug Development for the First Time--Findings Presented at ESMO 2021

SEOUL, South Korea, Sept. 17, 2021 /PRNewswire/ -- A leading medical AI provider Lunit today announced that its AI for tissue analysis has been applied in a clinical trial for drug development, accurately predicting the patients' response to immunotherapy. Including this major finding, the compan...

2021-09-17 21:00 2128

InnoCare and Keymed Jointly Announce Approval of Clinical Trial of CD20xCD3 Bispecific Antibody CM355

BEIJING, Sept. 17, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969) and Keymed Biosciences (HKEX: 02162) jointly announced today that the Investigational New Drug (IND) of CM355, a CD20xCD3 bispecific antibody developed by a joint venture between the two companies called Tiannuojiancheng Pharm...

2021-09-17 20:00 5988

The NDA of Henlius Novel Anti-PD-1 mAb Serplulimab for First-Line Treatment of sqNSCLC Accepted by China's NMPA, Phase 3 MRCT Met its Primary Endpoint

SHANGHAI, Sept. 17, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the New Drug Application (NDA) of Serplulimab Injection (HLX10), a novel anti-PD-1 monoclonal antibody (mAb) independently developed by the company, in combination with carboplatin and albumin-bound ...

2021-09-17 20:00 4967

111, Inc. Announces Participation in the Cantor Virtual Global Healthcare Conference

SHANGHAI, Sept. 17, 2021 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that Senior Vice President, Investor Relations and...

2021-09-17 19:00 4814

Arctic Vision Announces Addition of Novel Mydriatic Drug MydCombi™ (ARVN004) to Eyenovia Commercialization Deal

SHANGHAI, Sept. 16, 2021 /PRNewswire/ -- Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies, announced today that it will expand its exclusive license agreement with Eyenovia, Inc. (NASDAQ: EYEN) to include a third asset, MydCombi™, for development and commerc...

2021-09-17 08:00 2105

Bridge Biotherapeutics Presents Pre-Clinical Data of BBT-176 at the European Society for Medical Oncology (ESMO) Virtual Congress 2021

* Pre-clinical data exploring the in vitro and in vivo efficacy of BBT-176 will be disclosed via an ePoster at the ESMO Congress 2021 * Patient dosing for the phase 1/2 clinical study of BBT-176 was initiated in April 2021…the topline data of the first-in-human, dose escalation study is expec...

2021-09-17 06:00 2363

COVID-19 Scoop: Epoch-Making GoldenBiotech's Oral COVID-19 New Drug Trial Got Green Light from the FDA to Extend Recruiting Severe COVID-19 Patients

TAIPEI, Sept.16, 2021 /PRNewswire/ -- Golden Biotechnology Corp.(TPEx:4132) ("GoldenBiotech", GBC), a leading Taiwanese biopharmaceutical company, announces that its oral investigational new drug Antroquinonol (HOCENA®) has made headway withCOVID-19 treatment development in more broaden clinical ...

2021-09-16 18:05 2769

COVID-19 Scoop: Epoch-Making GoldenBiotech's Oral COVID-19 New Drug Trial Got Green Light from the FDA to Extend Recruiting Severe COVID-19 Patients

Laekna Therapeutics reported positive results in two clinical studies for the treatment of various stages of prostate cancer at the ESMO Congress

SHANGHAI and WARREN, New Jersey, Sept. 16, 2021 /PRNewswire/ -- Laekna Therapeutics, an emerging innovative biotech company based inChina's "Zhangjiang Pharma Valley" andNew Jersey, USA, focusing on the development of ground-breaking innovative therapies to treat cancer and liver diseases, repor...

2021-09-16 17:06 1984

GeneQuantum announces two key leadership appointments

SUZHOU, China, Sept. 15, 2021 /PRNewswire/ -- GeneQuantum Healthcare, an industry-leading biotech company dedicated to the next generation bioconjugate drugs based on the innovative intelligent ligase-dependent conjugation (iLDC) technology platform, announced the appointment of Dr.Li Wan as the ...

2021-09-16 09:00 1968

Prenetics, a Global Leader in Genomic and Diagnostic Testing, to Become Publicly Traded on the Nasdaq via Merger with Adrian Cheng's Artisan Acquisition Corp.

* Prenetics' mission is to disrupt and decentralise the healthcare industry with a global opportunity of overUS$1.3 trillion. * Prenetics' multi-product healthcare ecosystem strategy is driven by prevention focused genomic testing, rapid diagnostics for COVID-19 and infectious diseases, and c...

2021-09-16 06:00 9696

US Patent and Trademark Office grants new patent for DEP® cabazitaxel, one of Starpharma's phase 2 clinical-stage cancer treatments

MELBOURNE, Australia, Sept. 15, 2021 /PRNewswire/ -- DEP® cabazitaxel is a proprietary nanoparticle version of leading prostate cancer drug cabazitaxel (Jevtana®), which had global sales of US$536 million in 2020. Starpharma

2021-09-15 15:27 3241

Peijia Medical Announces First Patient Implant in the Clinical Trial of its Third-Generation Transcatheter Aortic Valve System TaurusNXT®

SUZHOU, China, Sept. 14, 2021 /PRNewswire/ -- Peijia Medical today announced the initiation of its multi-center clinical trial for TaurusNXT®, the third-generation transcatheter aortic valve ("TAVR") system, following the first successful patient implant in Zhongshan Hospital of Fudan Univers...

2021-09-14 22:11 5280

New Therapy to Treat Advanced Small Cell Lung Cancer Approved for Australian Patients

Highlights: * ZEPZELCA® (lurbinectedin) is the first new therapy approved to treat second-line metastatic SCLC inAustralia in more than 20 years * * ZEPZELCA approval granted under a provisional regulatory pathway * US FDA and TGA collaborated via 'Project Orbis' to accelerate avail...

2021-09-14 18:57 2309

PharmAbcine to Participate in ACCESS CHINA Biotech Forum

DAEJEON, South Korea, Sept. 13, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the Company will virtually participate in ACCESSCHINA Biotech Forum. The event will...

2021-09-13 20:00 1904

I-Mab Added to FTSE ESG Index Series

SHANGHAI and GAITHERSBURG, Md., Sept. 13, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that I-Mab will be added to the following FTSE ESG (Env...

2021-09-13 20:00 5231

Harbour BioMed Announces Phase I Study Positive Results on Next-Generation Anti-CTLA-4 Antibody HBM4003

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Sept. 13, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced positive results from its phase I dose escalation clinical trial of HBM4003 in solid tumors in Australia (the "phase I study"). The clinical data abstract has...

2021-09-13 14:34 3566

Samsung Biologics Joins Frontier 1.5D Project as part of 2050 Carbon Neutral Initiative

INCHEON, South Korea, Sept. 13, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization, announced the signing of an MOU today to participate in the Frontier 1.5D initiative to develop a climate risk management model as part...

2021-09-13 12:41 2674

Samsung Biologics Joins Frontier 1.5D Project as part of 2050 Carbon Neutral Initiative

Kazia Therapeutics to Present at HC Wainwright 23rd Annual Global Investment Conference

SYDNEY, Sept. 10, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, DrJames Garner, will be presenting at the HC Wainwright 23rd Annual Global Investment Conference, to be held virtually from13-...

2021-09-11 00:30 21003

1 ... 255 256 257258259 260 261